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Background
Conventional chemotherapy for locally advanced pan-
creatic cancer (LAPC) and metastatic PC (MPC) is asso-
ciated with clinical toxicities, dismal response, and poor
survival rates. Novel approaches are needed. Preclinical
studies show that bispecific antibody armed T cells exhi-
bit cytotoxicity, proliferate, and secrete cytokines(CCR
12:569, 2006) and that anti-CD3 x anti-EGFR Bispecific
antibody Armed T cells (EGFR BATs) can target and
kill EGFR+ colon and pancreatic cancer cells (CCR 12:
183, 2006). We conducted a Phase I using EGFR BATs
in LAPC, MPC and colorectal cancer to determine
safety, feasibility, efficacy, and immune responses.
Methods
Peripheral blood mononuclear cells from leukapheresis
were stimulated with anti-CD3 and IL-2 to produce
activated T cells that were armed with EGFRBi to create
EGFR BATs and cryopreserved. Patients with colorectal
cancer (6), LAPC (3), and MPC (2) were treated with
EGFR BATs after 1 cycle of FOLFOX6 (oxaliplatin and
leucovorin, 5 FU) given to create immune space. The
doses of BATs in this Phase I trial were 10, 20, and 40 x
109 BATs/infusion given in 3 weekly infusions with a
booster infusion at 3 months.
Results
We report the data on pancreatic cancer patients in the
study. One patient failed to grow activated T cells. Of 5 PC
patients in the study, 4 received 4 infusions, and 1 received
3 infusions. There were no dose limiting toxicities with an
average of 48 x 109 BATs (9.3 -74 x 109) infused. Grade
1-2 headaches, fevers, chills and blood pressure changes
were observed. Two patients (IT20091 and IT20104) went
into CR after restarting chemotherapy after “apparent”
progression of disease. One patient (IT20102) had stable
disease with near PR (↓27% of an index lesion) for 229
days. IT20104, who received 3 infusions, had a lymph node
increased by >50%, was given chemotherapy, and went into
CR after chemotherapy. Immune responses to PC lines
were detected in the PBMC. Time to progression was 71,
138, 186, 211, and 229 days with a median time to progres-
sion of 186 days, and OS was 297, 346, 409, 436, and
677 days with a median OS 14.5 months.
Conclusions
Stable disease, encouraging increased times to progression
and survival times, and clinical responses after chemother-
apy suggest that EGFR BATs infusions have clinical activity
in PC. An interesting observation is that immunotherapy
may be altering the tumor microenvironment or tumor to
improve chemotherapy responses.
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